Abstract
In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today’s predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Keywords: Quinolone, fluoroquinolone, topoisomerase, gyrase, topo II, topo IV, antitumor, anticancer, cytotoxic, antibacterial, selectivity, Paul Ehrlich, magic bullet, doxorubicin, etoposide, vosaroxin, quarfloxin, G quadruplex.
Current Medicinal Chemistry
Title:A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone
Volume: 23 Issue: 6
Author(s): Gregory S. Bisacchi and Michael R. Hale
Affiliation:
Keywords: Quinolone, fluoroquinolone, topoisomerase, gyrase, topo II, topo IV, antitumor, anticancer, cytotoxic, antibacterial, selectivity, Paul Ehrlich, magic bullet, doxorubicin, etoposide, vosaroxin, quarfloxin, G quadruplex.
Abstract: In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today’s predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Export Options
About this article
Cite this article as:
Bisacchi S. Gregory and Hale R. Michael, A “Double-Edged” Scaffold: Antitumor Power within the Antibacterial Quinolone, Current Medicinal Chemistry 2016; 23 (6) . https://dx.doi.org/10.2174/0929867323666151223095839
DOI https://dx.doi.org/10.2174/0929867323666151223095839 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Membrane Fusion as a Target for Antiviral Therapy
Anti-Infective Agents in Medicinal Chemistry Recent developments and opportunities in fighting COVID-19
Coronaviruses Use of the Genus <i>Satureja</i> as Food Supplement: Possible Modulation of the Immune System <i>via</i> Intestinal Microbiota During SARS-CoV-2 Infection
Anti-Infective Agents Mutasynthesis of Medicinally Significant Natural Products Through Manipulation of Gene Governing Starter Unit
Current Organic Chemistry Novel Aminopeptidase N Inhibitors with Improved Antitumor Activities
Letters in Drug Design & Discovery Application of Fluorine in Drug Design During 2010-2015 Years: A Mini-Review
Mini-Reviews in Medicinal Chemistry The Role of Coagulation in Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Pharmacophore Modeling, Synthesis, Scaffold Hopping and Biological β- Hematin Inhibition Interaction Studies for Anti-malaria Compounds
Current Topics in Medicinal Chemistry Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Ethnobotany, Pharmacological Activities and Bioavailability Studies on “King of Bitters” (Kalmegh): A Review (2010-2020)
Combinatorial Chemistry & High Throughput Screening Cell Penetrating Peptide Delivery of Splice Directing Oligonucleotides as a Treatment for Duchenne Muscular Dystrophy
Current Pharmaceutical Design The Redox Regulation of Thiol Dependent Signaling Pathways in Cancer
Current Pharmaceutical Design Editorial [Hot Topic: SARS-CoV: A Scenario of Modern Drug Design (Executive Editor: X. Huang)]
Current Pharmaceutical Design Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II)
Current Pharmaceutical Design Covid-19: Urgent Call to Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Virtual Screening An Effective Tool for Lead Structure Discovery
Current Pharmaceutical Design Loneliness and Social Isolation: Determinants of Cardiovascular Outcomes
Current Cardiology Reviews A Further Step Toward an Optimal Ensemble of Classifiers for Peptide Classification, a Case Study: HIV Protease
Protein & Peptide Letters Antiviral Potential of Medicinal Plants for the COVID-19
Anti-Infective Agents